Drug Profile
Research programme: fibrotic disorder therapeutics - Inventiva Pharma
Alternative Names: GEVLatest Information Update: 22 Jun 2023
Price :
$50
*
At a glance
- Originator Inventiva Pharma
- Class Antifibrotics; Small molecules
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis
Most Recent Events
- 22 Jun 2023 Early research is ongoing in France (Inventiva Pharma pipeline, June 2023)
- 28 Oct 2022 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in France
- 22 Oct 2020 Early research is ongoing in France (Inventiva Pharma pipeline, October 2020)